Pizotifen (BC 105) in migraine prophylaxis.

Article Details

Citation
Copy to clipboard

Carroll JD, Maclay WP

Pizotifen (BC 105) in migraine prophylaxis.

Curr Med Res Opin. 1975;3(2):68-71. doi: 10.1185/03007997509113649 .

PubMed ID
1095308 [ View in PubMed
]
Abstract

Pizotifen, an antaminic, was investigated in a double-blind placebo controlled trial to evaluate its efficacy in migraine prophylaxis. It was found to be and effective prophylactic in a proportion of migraine patients, reducing the frequency as well as the severity of headaches. Some patients showed weight gain. Several patients have continued treatment for up to 2 years with good control of their migraine and a reduction in the amount of medicament required for the acute attack.

DrugBank Data that Cites this Article

Drugs